The administration of BDNF and GDNF to the brain via PLGA microparticles patterned within a degradable PEG-based hydrogel: Protein distribution and the glial response.

Tailored delivery of neurotrophic factors (NFs) is a critical challenge that continues to inhibit strategies for guidance of axonal growth in vivo. Of particular importance is the ability to recreate innervation of distant brain regions by transplant tissue, for instance rebuilding the nigrostriatal track, one focus in Parkinson's disease research. Many strategies have utilized polymer drug delivery to target NF release in space and time, but combinatorial approaches are needed to deliver multiple NFs at relevant therapeutic times and locations without toxic side effects. Here we engineered a paradigm of PLGA microparticles entrapped within a degradable PEG-based hydrogel device to locally release two different types of NFs with two different release profiles. Hydrogel/microparticle devices were developed and analyzed for their ability to release GDNF in the caudal area of the brain, near the substantia nigra, or BDNF in the rostral area, near the striatum. The devices delivered their respective NFs in a region localized to within 100 μm of the bridge, but not exclusively to the targeted rostral or caudal ends. BDNF was slowly released over a 56-day period, whereas a bolus of GDNF was released around 28 days. The timed delivery of NFs from implanted devices significantly reduced the microglial response relative to sham surgeries. Given the coordinated drug delivery ability and reduced localized inflammatory response, this multifaceted PEG hydrogel/PLGA microparticle strategy may be a useful tool for further development in combining tissue engineering and drug delivery, and recreating the nigrostriatal track.

[1]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[2]  Yang D. Teng,et al.  Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells , 2007, Proceedings of the National Academy of Sciences.

[3]  M A Tracy,et al.  Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted into the Brain , 1999, Cell transplantation.

[4]  S. Wiegand,et al.  BDNF Enhances the Functional Reinnervation of the Striatum by Grafted Fetal Dopamine Neurons , 1996, Experimental Neurology.

[5]  Blair R. Leavitt,et al.  Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.

[6]  M. Mahoney,et al.  Impact of lactic acid on cell proliferation and free radical‐induced cell death in monolayer cultures of neural precursor cells , 2009, Biotechnology and bioengineering.

[7]  Redmond De Cellular replacement therapy for Parkinson's disease--where we are today? , 2002 .

[8]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[9]  A. Benraiss,et al.  Adenoviral Brain-Derived Neurotrophic Factor Induces Both Neostriatal and Olfactory Neuronal Recruitment from Endogenous Progenitor Cells in the Adult Forebrain , 2001, The Journal of Neuroscience.

[10]  O. Isacson,et al.  Immunophilin Ligands and GDNF Enhance Neurite Branching or Elongation from Developing Dopamine Neurons in Culture , 2000, Experimental Neurology.

[11]  G. Siegel,et al.  Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain , 2000, Brain Research Reviews.

[12]  M. Murer,et al.  Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease , 2001, Progress in Neurobiology.

[13]  D. Kirik,et al.  Long‐term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system , 2003, The European journal of neuroscience.

[14]  A. Björklund,et al.  Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. , 1996, Neuroscience.

[15]  E. Huang,et al.  Neurotrophins: roles in neuronal development and function. , 2001, Annual review of neuroscience.

[16]  M. Shive,et al.  Biodegradation and biocompatibility of PLA and PLGA microspheres , 1997 .

[17]  R. Roth,et al.  Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non‐human primate after overexpression of GDNF , 2009, The Journal of comparative neurology.

[18]  Jeffrey A. Hubbell,et al.  Bioerodible hydrogels based on photopolymerized poly(ethylene glycol)-co-poly(.alpha.-hydroxy acid) diacrylate macromers , 1993 .

[19]  G. Yancopoulos,et al.  Neurotrophic Factor Receptors and Their Signal Transduction Capabilities in Rat Astrocytes , 1994, The European journal of neuroscience.

[20]  J. Fawcett,et al.  The Time Course of Loss of Dopaminergic Neurons and the Gliotic Reaction Surrounding Grafts of Embryonic Mesencephalon to the Striatum , 1996, Experimental Neurology.

[21]  A. Heller,et al.  Glial-derived neurotrophic factor (GDNF) induced morphological differentiation of an immortalized monoclonal hybrid dopaminergic cell line of mesencephalic neuronal origin , 1996, Brain Research.

[22]  R. Ridley,et al.  Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease , 2005, The Journal of Neuroscience.

[23]  E. Tolosa,et al.  BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. , 1999, Journal of neuropathology and experimental neurology.

[24]  M. Mahoney,et al.  Development of porous PEG hydrogels that enable efficient, uniform cell-seeding and permit early neural process extension. , 2009, Acta biomaterialia.

[25]  T. Dawson,et al.  Diagnosis and treatment of Parkinson disease: molecules to medicine. , 2006, The Journal of clinical investigation.

[26]  J. Benoit,et al.  Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. , 2004, Biomaterials.

[27]  Stephanie J Bryant,et al.  In situ forming degradable networks and their application in tissue engineering and drug delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[28]  E. Clarkson,et al.  Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats , 1998, Brain Research.

[29]  Erwan Bezard,et al.  Novel pharmacological targets for the treatment of Parkinson's disease , 2006, Nature Reviews Drug Discovery.

[30]  Steven A. Johnson,et al.  BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease , 1991, Neuron.

[31]  M. Mahoney,et al.  Biocompatibility of poly(ethylene glycol)-based hydrogels in the brain: an analysis of the glial response across space and time. , 2010, Journal of biomedical materials research. Part A.

[32]  S. Willerth,et al.  Approaches to neural tissue engineering using scaffolds for drug delivery. , 2007, Advanced drug delivery reviews.

[33]  M. Sofroniew,et al.  Essential protective roles of reactive astrocytes in traumatic brain injury. , 2006, Brain : a journal of neurology.

[34]  H. Scharfman,et al.  Brain-derived neurotrophic factor. , 2004, Growth factors.

[35]  Stanley J. Wiegand,et al.  Intraventricular Administration of BDNF Increases the Number of Newly Generated Neurons in the Adult Olfactory Bulb , 1998, Molecular and Cellular Neuroscience.

[36]  Robert Langer,et al.  Stimulation of neurite outgrowth by neurotrophins delivered from degradable hydrogels. , 2006, Biomaterials.

[37]  J. Benoit,et al.  Analysis of brain biocompatibility of drug-releasing biodegradable microspheres by scanning and transmission electron microscopy. , 2001, Journal of neurosurgery.

[38]  S. Tzeng,et al.  Photopolymerizable nanoarray hydrogels deliver CNTF and promote differentiation of neural stem cells , 2010 .

[39]  W. Mark Saltzman,et al.  Building drug delivery into tissue engineering design , 2002, Nature Reviews Drug Discovery.

[40]  G. Yancopoulos,et al.  BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra , 1991, Nature.

[41]  W. Saltzman,et al.  Controlled release of proteins to tissue transplants for the treatment of neurodegenerative disorders. , 1996, Journal of pharmaceutical sciences.

[42]  J. Benoit,et al.  Pharmacologically active microcarriers releasing glial cell line - derived neurotrophic factor: Survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats. , 2007, Biomaterials.

[43]  K. Unsicker,et al.  TGF‐beta superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity. , 1995, The EMBO journal.

[44]  W. Mark Saltzman,et al.  Localized Delivery of Proteins in the Brain: Can Transport Be Customized? , 1998, Pharmaceutical Research.

[45]  J. Benoit,et al.  Effect of GDNF-releasing biodegradable microspheres on the function and the survival of intrastriatal fetal ventral mesencephalic cell grafts. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[46]  J. de Vellis,et al.  Stem cell‐based cell therapy in neurological diseases: A review , 2009, Journal of neuroscience research.

[47]  M. Mahoney,et al.  Impact of degradable macromer content in a poly(ethylene glycol) hydrogel on neural cell metabolic activity, redox state, proliferation, and differentiation. , 2010, Tissue engineering. Part A.

[48]  Philippe Menei,et al.  In vitro study of GDNF release from biodegradable PLGA microspheres. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[49]  Stanley J. Wiegand,et al.  Infusion of Brain-Derived Neurotrophic Factor into the Lateral Ventricle of the Adult Rat Leads to New Neurons in the Parenchyma of the Striatum, Septum, Thalamus, and Hypothalamus , 2001, The Journal of Neuroscience.

[50]  J. Zimmer,et al.  Effects of Donor Age and Brain-Derived Neurotrophic Factor on the Survival of Dopaminergic Neurons and Axonal Growth in Postnatal Rat Nigrostriatal Cocultures , 1996, Experimental Neurology.

[51]  M. Mahoney,et al.  Effect of macromer weight percent on neural cell growth in 2D and 3D nondegradable PEG hydrogel culture. , 2010, Journal of biomedical materials research. Part A.

[52]  F. Aloisi Immune function of microglia , 2001, Glia.

[53]  J. Lanciego,et al.  Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[54]  T. Blunk,et al.  Towards controlled release of BDNF--manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[55]  M. Mahoney,et al.  Biocompatibility of PEG-Based Hydrogels in Primate Brain , 2008, Cell transplantation.

[56]  J. Benoit,et al.  Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease , 2004, Neuroscience Letters.

[57]  A. Pérez-Bouza,et al.  Effect of GDNF on differentiation of cultured ventral mesencephalic dopaminergic and non-dopaminergic calretinin-expressing neurons , 2005, Brain Research.

[58]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[59]  Kristi S Anseth,et al.  Three-dimensional growth and function of neural tissue in degradable polyethylene glycol hydrogels. , 2006, Biomaterials.

[60]  S. Maier,et al.  Intrathecal polymer-based interleukin-10 gene delivery for neuropathic pain. , 2006, Neuron glia biology.

[61]  P. Brundin,et al.  Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. , 2006, International journal of pharmaceutics.

[62]  Kristi S. Anseth,et al.  Predicting Controlled-Release Behavior of Degradable PLA-b-PEG-b-PLA Hydrogels , 2001 .

[63]  G. L. Curran,et al.  Macromolecular permeability across the blood-nerve and blood-brain barriers , 1994 .